Protein Kinase C As the Receptor for the Phorbol Ester Tumor Promoters: Sixth Rhoads Memorial Award Lecture1
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
The Mammalian TRPC Cation Channels
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1742 (2004) 21–36 http://www.elsevier.com/locate/bba Review The mammalian TRPC cation channels Guillermo Vazquez, Barbara J. Wedel, Omar Aziz, Mohamed Trebak, James W. Putney Jr.* The Calcium Regulation Section, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, 111 TW Alexander Dr., Research Triangle Park, NC 27709, United States Received 3 August 2004; received in revised form 27 August 2004; accepted 28 August 2004 Available online 11 September 2004 Abstract Transient Receptor Potential-Canonical (TRPC) channels are mammalian homologs of Transient Receptor Potential (TRP), a Ca2+- permeable channel involved in the phospholipase C-regulated photoreceptor activation mechanism in Drosophila. The seven mammalian TRPCs constitute a family of channels which have been proposed to function as store-operated as well as second messenger-operated channels in a variety of cell types. TRPC channels, together with other more distantly related channel families, make up the larger TRP channel superfamily. This review summarizes recent findings on the structure, regulation and function of the apparently ubiquitous TRPC cation channels. Published by Elsevier B.V. Keywords: Ion channel; Calcium channel; Non-selective cation channel; TRP channel; TRPC channel; Capacitative calcium entry; Store-operated channel; Second messenger-operated channel; Inositol trisphosphate receptor; Diacylglycerol; Phospholipase C 1. Origin, classification and nomenclature of TRPCs member, the vanilloid receptor; and the TRPM family, with eight members (TRPM1–8), named after the original The recognition that the protein product derived from member, melastatin (Fig. -
S41598-020-80397-9.Pdf
www.nature.com/scientificreports OPEN Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes Jason K. Cullen1, Glen M. Boyle1,2,3,7*, Pei‑Yi Yap1, Stefan Elmlinger1, Jacinta L. Simmons1, Natasa Broit1, Jenny Johns1, Blake Ferguson1, Lidia A. Maslovskaya1,4, Andrei I. Savchenko4, Paul Malek Mirzayans4, Achim Porzelle4, Paul V. Bernhardt4, Victoria A. Gordon5, Paul W. Reddell5, Alberto Pagani6, Giovanni Appendino6, Peter G. Parsons1,3 & Craig M. Williams4* The long‑standing perception of Protein Kinase C (PKC) as a family of oncoproteins has increasingly been challenged by evidence that some PKC isoforms may act as tumor suppressors. To explore the hypothesis that activation, rather than inhibition, of these isoforms is critical for anticancer activity, we isolated and characterized a family of 16 novel phorboids closely‑related to tigilanol tiglate (EBC‑46), a PKC‑activating epoxytigliane showing promising clinical safety and efcacy for intratumoral treatment of cancers. While alkyl branching features of the C12‑ester infuenced potency, the 6,7‑epoxide structural motif and position was critical to PKC activation in vitro. A subset of the 6,7‑epoxytiglianes were efcacious against established tumors in mice; which generally correlated with in vitro activation of PKC. Importantly, epoxytiglianes without evidence of PKC activation showed limited antitumor efcacy. Taken together, these fndings provide a strong rationale to reassess the role of PKC isoforms in cancer, and suggest in some situations their activation can be a promising strategy for anticancer drug discovery. Te Protein Kinase C (PKC) family of serine/threonine kinases was frst identifed almost 40 years ago1. -
Receptor-Mediated Modulation of Human Monocyte, Neutrophil, Lymphocyte, and Platelet Function by Phorbol Diesters
Receptor-mediated Modulation of Human Monocyte, Neutrophil, Lymphocyte, and Platelet Function by Phorbol Diesters BONNIE J. GOODWIN, Department of Medicine, Division of Hematology-Oncology, Duke University Medical Center, Durham, North Carolina 27710 J. BRICE WEINBERG, Department of Medicine, Division of Hematology-Oncology, Veterans Administration Medical Center and Duke University Medical Center, Durham, North Carolina 27705 A B S T R A C T The tumor promoting phorbol diesters creasing order of potency) inhibited [3H]PDBu binding elicit a variety of responses from normal and leukemic and elicited the various responses. Thus, these high blood cells in vitro by apparently interacting with cel- affinity, specific receptors for the phorbol diesters, lular receptors. The biologically active ligand [20-3H] present on monocytes, lymphocytes, PMN, and plate- phorbol 12,13-dibutyrate ([3H]PDBu) bound specifi- lets, mediate the pleiotypic effects induced by these cally to intact human lymphocytes, monocytes, poly- ligands. morphonuclear leukocytes (PMN), and platelets, but not to erythrocytes. Binding, which was comparable INTRODUCTION for all four blood cell types, occurred rapidly at 230 and 37°C, reaching a maximum by 20-30 min usually Tumor promoting agents are substances, which al- followed by a 30-40% decrease in cell associated ra- though noncarcinogenic themselves, cause tumor for- dioactivity over the next 30-60 min. The time course mation when applied repeatedly to mouse skin that for binding was temperature dependent with equilib- has been previously treated with a subthreshold dose rium binding occurring after 120-150 min at 4°C, of a carcinogen. The most potent promoters in the with no subsequent loss of cell-associated radioactivity mouse skin system are esters of the tetracyclic diter- at this temperature. -
Medically Useful Plant Terpenoids: Biosynthesis, Occurrence, and Mechanism of Action
molecules Review Medically Useful Plant Terpenoids: Biosynthesis, Occurrence, and Mechanism of Action Matthew E. Bergman 1 , Benjamin Davis 1 and Michael A. Phillips 1,2,* 1 Department of Cellular and Systems Biology, University of Toronto, Toronto, ON M5S 3G5, Canada; [email protected] (M.E.B.); [email protected] (B.D.) 2 Department of Biology, University of Toronto–Mississauga, Mississauga, ON L5L 1C6, Canada * Correspondence: [email protected]; Tel.: +1-905-569-4848 Academic Editors: Ewa Swiezewska, Liliana Surmacz and Bernhard Loll Received: 3 October 2019; Accepted: 30 October 2019; Published: 1 November 2019 Abstract: Specialized plant terpenoids have found fortuitous uses in medicine due to their evolutionary and biochemical selection for biological activity in animals. However, these highly functionalized natural products are produced through complex biosynthetic pathways for which we have a complete understanding in only a few cases. Here we review some of the most effective and promising plant terpenoids that are currently used in medicine and medical research and provide updates on their biosynthesis, natural occurrence, and mechanism of action in the body. This includes pharmacologically useful plastidic terpenoids such as p-menthane monoterpenoids, cannabinoids, paclitaxel (taxol®), and ingenol mebutate which are derived from the 2-C-methyl-d-erythritol-4-phosphate (MEP) pathway, as well as cytosolic terpenoids such as thapsigargin and artemisinin produced through the mevalonate (MVA) pathway. We further provide a review of the MEP and MVA precursor pathways which supply the carbon skeletons for the downstream transformations yielding these medically significant natural products. Keywords: isoprenoids; plant natural products; terpenoid biosynthesis; medicinal plants; terpene synthases; cytochrome P450s 1. -
Targeting Protein Kinase C in Glioblastoma Treatment
biomedicines Review Targeting Protein Kinase C in Glioblastoma Treatment Noelia Geribaldi-Doldán 1,2,† , Irati Hervás-Corpión 2,3,†, Ricardo Gómez-Oliva 2,4 , Samuel Domínguez-García 2,4, Félix A. Ruiz 2,3,5 , Irene Iglesias-Lozano 2,3, Livia Carrascal 2,6 , Ricardo Pardillo-Díaz 1,2, José L. Gil-Salú 2,3, Pedro Nunez-Abades 2,6 , Luis M. Valor 2,3,7,* and Carmen Castro 2,4,* 1 Departamento de Anatomía y Embriología Humanas, Facultad de Medicina, Universidad de Cádiz, 11003 Cádiz, Spain; [email protected] (N.G.-D.); [email protected] (R.P.-D.) 2 Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), 11009 Cádiz, Spain; [email protected] (I.H.-C.); [email protected] (R.G.-O.); [email protected] (S.D.-G.); [email protected] (F.A.R.); [email protected] (I.I.-L.); [email protected] (L.C.); [email protected] (J.L.G.-S.); [email protected] (P.N.-A.) 3 Unidad de Investigación, Hospital Universitario Puerta del Mar de Cádiz, 11009 Cádiz, Spain 4 Área de Fisiología, Facultad de Medicina, Universidad de Cádiz, 11003 Cádiz, Spain 5 Área de Nutrición, Facultad de Medicina, Universidad de Cádiz, 11003 Cádiz, Spain 6 Departamento de Fisiología, Facultad de Farmacia, Universidad de Sevilla, 41012 Sevilla, Spain 7 Currently at Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), 03010 Alicante, Spain * Correspondence: [email protected] (L.M.V.); [email protected] (C.C.) † These authors contributed equally to this work. Abstract: Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor and is associ- ated with a poor prognosis. -
TRPV Channels and Their Pharmacological Modulation
Cellular Physiology Cell Physiol Biochem 2021;55(S3):108-130 DOI: 10.33594/00000035810.33594/000000358 © 2021 The Author(s).© 2021 Published The Author(s) by and Biochemistry Published online: online: 28 28 May May 2021 2021 Cell Physiol BiochemPublished Press GmbH&Co. by Cell Physiol KG Biochem 108 Press GmbH&Co. KG, Duesseldorf SeebohmAccepted: 17et al.:May Molecular 2021 Pharmacology of TRPV Channelswww.cellphysiolbiochem.com This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna- tional License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Review Beyond Hot and Spicy: TRPV Channels and their Pharmacological Modulation Guiscard Seebohma Julian A. Schreibera,b aInstitute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany, bInstitut für Pharmazeutische und Medizinische Chemie, Westfälische Wilhelms-Universität Münster, Münster, Germany Key Words TRPV • Molecular pharmacology • Capsaicin • Ion channel modulation • Medicinal chemistry Abstract Transient receptor potential vanilloid (TRPV) channels are part of the TRP channel superfamily and named after the first identified member TRPV1, that is sensitive to the vanillylamide capsaicin. Their overall structure is similar to the structure of voltage gated potassium channels (Kv) built up as homotetramers from subunits with six transmembrane helices (S1-S6). Six TRPV channel subtypes (TRPV1-6) are known, that can be subdivided into the thermoTRPV 2+ (TRPV1-4) and the Ca -selective TRPV channels (TRPV5, TRPV6). Contrary to Kv channels, TRPV channels are not primary voltage gated. All six channels have distinct properties and react to several endogenous ligands as well as different gating stimuli such as heat, pH, mechanical stress, or osmotic changes. -
Ca2+ Signaling by TRPV4 Channels in Respiratory Function and Disease
cells Review Ca2+ Signaling by TRPV4 Channels in Respiratory Function and Disease Suhasini Rajan, Christian Schremmer, Jonas Weber, Philipp Alt, Fabienne Geiger and Alexander Dietrich * Experimental Pharmacotherapy, Walther-Straub-Institute of Pharmacology and Toxicology, Member of the German Center for Lung Research (DZL), LMU-Munich, 80336 Munich, Germany; [email protected] (S.R.); [email protected] (C.S.); [email protected] (J.W.); [email protected] (P.A.); [email protected] (F.G.) * Correspondence: [email protected] Abstract: Members of the transient receptor potential (TRP) superfamily are broadly expressed in our body and contribute to multiple cellular functions. Most interestingly, the fourth member of the vanilloid family of TRP channels (TRPV4) serves different partially antagonistic functions in the respiratory system. This review highlights the role of TRPV4 channels in lung fibroblasts, the lung endothelium, as well as the alveolar and bronchial epithelium, during physiological and pathophysiological mechanisms. Data available from animal models and human tissues confirm the importance of this ion channel in cellular signal transduction complexes with Ca2+ ions as a second messenger. Moreover, TRPV4 is an excellent therapeutic target with numerous specific compounds regulating its activity in diseases, like asthma, lung fibrosis, edema, and infections. Keywords: TRP channels; TRPV4; respiratory system; lung; endothelium; epithelium; Ca2+ signaling; signal transduction Citation: Rajan, S.; Schremmer, C.; Weber, J.; Alt, P.; Geiger, F.; Dietrich, A. Ca2+ Signaling by TRPV4 1. Introduction Channels in Respiratory Function and Cation selective ion channels of the transient receptor potential (TRP) superfamily con- Disease. -
Transient Receptor Potential Channels As Drug Targets: from the Science of Basic Research to the Art of Medicine
1521-0081/66/3/676–814$25.00 http://dx.doi.org/10.1124/pr.113.008268 PHARMACOLOGICAL REVIEWS Pharmacol Rev 66:676–814, July 2014 Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: DAVID R. SIBLEY Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine Bernd Nilius and Arpad Szallasi KU Leuven, Department of Cellular and Molecular Medicine, Laboratory of Ion Channel Research, Campus Gasthuisberg, Leuven, Belgium (B.N.); and Department of Pathology, Monmouth Medical Center, Long Branch, New Jersey (A.S.) Abstract. ....................................................................................679 I. Transient Receptor Potential Channels: A Brief Introduction . ...............................679 A. Canonical Transient Receptor Potential Subfamily . .....................................682 B. Vanilloid Transient Receptor Potential Subfamily . .....................................686 C. Melastatin Transient Receptor Potential Subfamily . .....................................696 Downloaded from D. Ankyrin Transient Receptor Potential Subfamily .........................................700 E. Mucolipin Transient Receptor Potential Subfamily . .....................................702 F. Polycystic Transient Receptor Potential Subfamily . .....................................703 II. Transient Receptor Potential Channels: Hereditary Diseases (Transient Receptor Potential Channelopathies). ......................................................704 -
Phlpping the Balance: Restoration of Protein Kinase C in Cancer
Biochemical Journal (2021) 478 341–355 https://doi.org/10.1042/BCJ20190765 Review Article PHLPPing the balance: restoration of protein kinase C in cancer Hannah Tovell and Alexandra C. Newton Downloaded from http://portlandpress.com/biochemj/article-pdf/478/2/341/902908/bcj-2019-0765c.pdf by University of California San Diego (UCSD) user on 29 January 2021 Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093, U.S.A Correspondence: Alexandra C. Newton ([email protected]) Protein kinase signalling, which transduces external messages to mediate cellular growth and metabolism, is frequently deregulated in human disease, and specifically in cancer. As such, there are 77 kinase inhibitors currently approved for the treatment of human disease by the FDA. Due to their historical association as the receptors for the tumour- promoting phorbol esters, PKC isozymes were initially targeted as oncogenes in cancer. However, a meta-analysis of clinical trials with PKC inhibitors in combination with chemo- therapy revealed that these treatments were not advantageous, and instead resulted in poorer outcomes and greater adverse effects. More recent studies suggest that instead of inhibiting PKC, therapies should aim to restore PKC function in cancer: cancer-asso- ciated PKC mutations are generally loss-of-function and high PKC protein is protective in many cancers, including most notably KRAS-driven cancers. These recent findings have reframed PKC as having a tumour suppressive function. This review focusses on a poten- tial new mechanism of restoring PKC function in cancer — through targeting of its nega- tive regulator, the Ser/Thr protein phosphatase PHLPP. -
A Proposed Common Mechanism by Which Phorbol Esters And
(CANCER RESEARCH 51, 4328-4335. August 15. I991| A Proposed Common Mechanism by Which Phorbol Esters and Epidermal Growth Factor Delay the Progression from G2 Phase to Mitosis of HeLa Cells through Phospholipid Metabolites' Marietta Kaszkin, Gerhard Fiirstenberger, James Richards, Lothar Seidler, and Volker Kinzel2 Institute of Experimental Pathology [M. K.. J. R., L. S., V. K.J and Institute of Biochemistry {G. F.], German Cancer Research Center, Im Neuenheimer Feld 280, D-6900 Heidelberg, Federal Republic of Germany ABSTRACT tumor promoters in the cell cycle of replicating cells (10) we observed a transient inhibition of the progression from G2 to The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA; also mitosis in HeLa cells induced by phorbol esters which carries called phorbol myristate acetate) and epidermal growth factor both the characteristics of a receptor-mediated response (11). The rapidly inhibit the transition of HeLa cells from <... phase to mitosis in a results led us to suppose that physiological factors such as reversible fashion with characteristics of a receptor-mediated response. EGF3 which elicit certain comparable metabolites should induce It was proposed that an intracellular mediator was responsible for this inhibition. In searching for a common mediator elicited by the action of a transient inhibition of the G2-M transition like that of phorbol both ligands, the time course of generation of phospholipid metabolites esters. This indeed was shown for EGF (12). In order to was compared with the cell cycle response of the G2 cohort monitored by approach the transduction mechanism the attention was thus time lapse analysis. The time course and the degree of mobilization of focused on biologically active metabolites of phospholipids diacylglycerols (DC) effected by TPA and by epidermal growth factor known to be elicited by EGF and by phorbol esters. -
5696.Full.Pdf
[CANCER RESEARCH 46, 5696-5700, November 1986] Enhanced Release of Hydrogen Peroxide and Metabolites of Arachidonic Acid by Macrophages from SENCAR Mice following Stimulation with Phorbol Esters1 James G. Lewis and Dolph O. Adams Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710 ABSTRACT genotoxic ROIs,2 and lipid oxidation products (8-10). Leuko cytes stimulated with phorbol esters also suffer breakage of Chronic inflammation has long been associated with carcinogenesis. their DNA, produce soluble low molecular weight clastogenic Phorbol esters which are potent promoters of tumors in mouse skin are factors, and induce increased rates of sister chromatid exchange also potent inflammatory agents in skin and cause inflammatory cells to in cm-illtu red mammalian cells (11-14). We have shown that release large quantities of reactive oxygen intermediates and oxidized murine peritoneal macrophages, stimulated with phorbol esters lipid products. SENCAR mice have been bred for their sensitivity to the or particulate inflammatory signals, induce 5,6-ring saturated promotion of tumors by phorbol esters and CS7BL/6 mice have been thymine bases in the DNA of cocultured mammalian cells (15, shown to be resistant. We quantified the release of H2O2 and metabolites 16). This process was inhibited by both catalase and nordihy- of arachidi mic acid by macrophages obtained from SENCAR and C57BL/ droguaiaretic acid (an inhibitor of arachidonic acid metabolism) 6 mice, following exposure to phorbol esters and other stimulants. The and was enhanced by Superoxide dismutase and indomethacin basal level for secretion of 112(): in resident peritoneal macrophages was (an inhibitor specific for cyclooxygenases). -
Negative Modulation of TRPM8 Channel Function by Protein Kinase C in Trigeminal Cold Thermoreceptor Neurons
International Journal of Molecular Sciences Article Negative Modulation of TRPM8 Channel Function by Protein Kinase C in Trigeminal Cold Thermoreceptor Neurons Bastián Rivera 1 , Matías Campos 1, Patricio Orio 2 , Rodolfo Madrid 1 and María Pertusa 1,* 1 Department of Biology, Facultad de Química y Biología, Universidad de Santiago de Chile, and Millennium Nucleus of Ion Channel-Associated Diseases (MiNICAD), 9160000 Santiago, Chile; [email protected] (B.R.); [email protected] (M.C.); [email protected] (R.M.) 2 Centro Interdisciplinario de Neurociencia de Valparaíso and Instituto de Neurociencia, Facultad de Ciencias, Universidad de Valparaíso, 2360102 Valparaíso, Chile; [email protected] * Correspondence: [email protected]; Tel.: +56-2-271-82955 Received: 30 April 2020; Accepted: 12 June 2020; Published: 22 June 2020 Abstract: TRPM8 is the main molecular entity responsible for cold sensing. This polymodal ion channel is activated by cold, cooling compounds such as menthol, voltage, and rises in osmolality. In corneal cold thermoreceptor neurons (CTNs), TRPM8 expression determines not only their sensitivity to cold, but also their role as neural detectors of ocular surface wetness. Several reports suggest that Protein Kinase C (PKC) activation impacts on TRPM8 function; however, the molecular bases of this functional modulation are still poorly understood. We explored PKC-dependent regulation of TRPM8 using Phorbol 12-Myristate 13-Acetate to activate this kinase. Consistently, recombinant TRPM8 channels, cultured trigeminal neurons, and free nerve endings of corneal CTNs revealed a robust reduction of TRPM8-dependent responses under PKC activation. In corneal CTNs, PKC activation decreased ongoing activity, a key parameter in the role of TRPM8-expressing neurons as humidity detectors, and also the maximal cold-evoked response, which were validated by mathematical modeling.